Loading data...
Psilocybin-Research.com Searchable psilocybin and psilocin bibliometric database.

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

Research workflow

Search, filter, export, analyze, and monitor psilocybin and psilocin publications with source labels, publication status, citation links, alerts, API access, and full SQLite download.

Databases used

  • PubMed
  • Crossref
  • Europe PMC
  • OpenAlex
  • medRxiv
  • bioRxiv
  • PsyArXiv
  • ClinicalTrials.gov

Psilocybin and psilocin research index

Find psilocybin and psilocin papers, preprints, trials, and citations with clear source context.

Database 4,054 indexed records
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Database 4,054 indexed records
4,054 Total Publications 3,914 Psilocybin Records 569 Psilocin Records 4,054 Search Matches 826 Journals 66 Research Topics
Published 3,317 Peer-reviewed / formal records
Preprints 450 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
PubMed 278 6.9% Active
Europe PMC 1,652 40.7% Active
OpenAlex 1,401 34.6% Active
ClinicalTrials.gov 287 7.1% Active
PsyArXiv 191 4.7% Active
bioRxiv 142 3.5% Active
Crossref 69 1.7% Active
Publication timeline 3,041 dated records
3,041 records since 2020
Annual records Cumulative line
Default publication index

Latest publications

4,054 records from the full SQLite publication database, sorted by newest first.

Result settings and export data
Updated Jul 5, 2026 01:22 UTC
Checking for newly indexed publications...
Page 44 of 203

Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models

The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some clinical and preclinical data suggest these putative benefits derive from direct analgesic effects. However, this possibility has not been comprehensively tested in preclinical models. Here, we show that psilocybin is not analgesic over a range of d...

The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.

Major depressive disorder is a debilitating condition, with many patients unresponsive to conventional monoaminergic antidepressants. Rapid-acting antidepressants such as ketamine and psilocybin offer promising alternatives, relieving symptoms within hours. Ketamine, an NMDA receptor antagonist, and psilocybin, a serotonergic psychedelic primarily targeting ...

Unknown journal 2025-07-06 Park D, Lee G, Lee WG, Kim B, Lee Y, Kim JW.

Explore the effect of psilocybin on depression and anxiety

Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeuti...

Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic Mice

Background/Objectives: Hallucinogenic substances such as psilocybin, psilocin, ergometrine, ergotamine, and lysergic acid diethylamide (LSD) have been demonstrated to enhance the force of contraction (FOC), in part due to the phosphorylation of phospholamban in human atrial preparations via 5-HT4 serotonin receptors and/or H2 histamine receptors. However, wh...

Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging

Conventional antidepressants show moderate efficacy in treating major depressive disorder. Psychedelic-assisted therapy holds promise, yet individual responses vary, underscoring the need for predictive tools to guide treatment selection. Here, we present graphTRIP (graph-based Treatment Response Interpretability and Prediction) - a geometric deep learning a...

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study

BACKGROUND: Obsessive-compulsive disorder (OCD) is a common and disabling condition. A large proportion of patients fail to respond to first-line treatment with serotonin reuptake inhibitors either selective serotonin reuptake inhibitors (SSRIs) or clomipramine. Preliminary evidence suggests psilocybin, a serotonin receptor agonist, might be efficacious. We ...

Psilocybin bei schwerer behandlungsresistenter Depression

Depressionserkrankungen, die auf mehrere Behandlungen nicht ansprechen, gelten als schwere, behandlungsresistente Depressionen (TRD). Studien mit Antidepressiva zeigen einen abnehmenden Effekt, wenn die die Erstbehandlung nicht erfolgreich ist. In einer offenen Studie des Sheppard Pratt Hospitals, Baltimore, wurden Sicherheit und Wirksamkeit der aus Pilzen g...

Fortschritte der Neurologie · Psychiatrie 2025-06-30 Authors unavailable

Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report

Background: Persisting symptoms after concussion is a complex syndrome warranting exploration into further treatment options. Emerging research highlights the potential of classic psychedelics, such as psilocybin, in managing neuropsychiatric conditions and promoting neuroprotection. Case Report: A case is presented of a 22-year-old male intercollegiate athl...

Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.

Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight - at times, bordering on the mystical - one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials have foun...

Exploring serotonergic psychedelics as a treatment for personality disorders.

Both psychotherapeutic interventions and pharmacological agents have demonstrated limited efficacy in the treatment of personality disorders (PDs). Emerging evidence suggests that psychedelic therapy, already showing promise in treating various psychiatric conditions commonly comorbid with PDs, may exert therapeutic effects by promoting adaptive changes in p...

What fMRI studies say about the nature of the psychedelic effect: a scoping review.

Research on psychedelic drugs, such as psilocybin, LSD or DMT, is a burgeoning field, with an increasing number of studies showing their promise in treatment of mental disorders as well as examining their mechanism of action. Determining their effect on the brain is crucial from clinical standpoint, but also offers highly promising avenues of advancement in ...

Unknown journal 2025-06-30 Beneš M, Páleníček T, Horáček J.

Efficient Acyloxymethylation of Psilocin and Other Tryptamines Yielding ACOM Prodrugs for Psychedelic-Assisted Therapy

ABSTRACT Acyloxymethyl (ACOM) derivatives of tryptamines such as the psychedelic drug psilocin and the anti-migraine drug sumatriptan bear potential as prodrugs. Previous synthetic approaches suffer from insufficient chemoselectivity between the desired functionalization of the phenolic (psilocin) or sulfonamide (sumatriptan) groups versus other reactive gro...

Chemical Composition and Biological Activities of Psilocybe Mushrooms: Gaps and Perspectives.

The Psilocybe genus is known for producing tryptamine alkaloids, specifically the compounds psilocybin and psilocin, which have shown antidepressant and anxiolytic potential. The presence of these alkaloids makes Psilocybe mushrooms promising sources of molecules with potential applications in the treatment of mental disorders. To explore this, a bibliograph...

Unknown journal 2025-06-30 Luz MA, Guedes HVS, Bisneto ABM, Jesus RA, Galdino TP, Oliveira LC

Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.

ImportancePsilocybin has demonstrated rapid and sustained antidepressant efficacy, with acute-phase effect sizes often more than double those for conventional antidepressants. However, concerns have been raised that high rates of functional unblinding in combination with trial participants with positive expectations of psychedelic use might bias treatment ou...

Unknown journal 2025-06-30 Hieronymus F, López E, Werin Sjögren H, Lundberg J.

Synthesis of Psilocin, Psilocybin and 5-MeO-DMT Succinate, All Labelled With Carbon-14 at the Indole 2-Position

ABSTRACT Three novel 14 C-labelled isotopologues of the psychoactive agents psilocin, psilocybin and 5-methoxy- N, N -dimethyltryptamine (5-MeO-DMT) were synthesised, all labelled at the 2-position of the indole. The syntheses involved incorporating the 3-dimethylaminoethyl substituent common to all three substances onto a 4- or 5-substituted indole intermed...

Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances

Psychoactive substances are compounds that can influence perception, consciousness, cognition, and emotions. The psychoactive substances caffeine, nicotine, cannabis, and psilocybin all originate from natural sources and can be used without complex processing or synthesis. Their natural availability has contributed to a long-standing history of human use and...

Untargeted analysis of psilocybin and non-psilocybin mushrooms using liquid chromatography quadrupole time of flight mass spectrometry

Psilocybin mushrooms, particularly those containing the psychoactive compounds psilocybin and psilocin, have attracted recent attention due to their potential therapeutic use for the treatment of psychological disorders. To use psilocybin mushrooms in a clinical context, it is important to understand their chemical composition more fully. An untargeted analy...

Unknown journal 2025-06-30 Islam S, Liden T, Goff R, Schug KA.

Live source coverage

4,054 indexed records across 8 active sources.

3,317Published
450Preprints
287Clinical trials
  1. PubMed 278 records · 6.9%
  2. Europe PMC 1,652 records · 40.7%
  3. OpenAlex 1,401 records · 34.6%
  4. ClinicalTrials.gov 287 records · 7.1%
  5. PsyArXiv 191 records · 4.7%
  6. bioRxiv 142 records · 3.5%
  7. Crossref 69 records · 1.7%
  8. medRxiv 34 records · 0.8%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.